Title | Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J, Bastidas R, LaBranche C, Allen JD, Copps J, Perrett HR, Rantalainen K, Cannac F, Yang YR, de la Peña ATorrents, Rocha RFroes, Berndsen ZT, Baker D, King NP, Sanders RW, Moore JP, Crotty S, Crispin M, Montefiori DC, Burton DR, Schief WR, Silvestri G, Ward AB |
Journal | Nat Commun |
Volume | 12 |
Issue | 1 |
Pagination | 4817 |
Date Published | 2021 Aug 10 |
ISSN | 2041-1723 |
Keywords | AIDS Vaccines, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibody Formation, Cryoelectron Microscopy, env Gene Products, Human Immunodeficiency Virus, Epitopes, Glycosylation, HIV Antibodies, HIV Infections, HIV-1, Humans, Macaca mulatta, Models, Molecular, Protein Conformation |
Abstract | Engineered ectodomain trimer immunogens based on BG505 envelope glycoprotein are widely utilized as components of HIV vaccine development platforms. In this study, we used rhesus macaques to evaluate the immunogenicity of several stabilized BG505 SOSIP constructs both as free trimers and presented on a nanoparticle. We applied a cryoEM-based method for high-resolution mapping of polyclonal antibody responses elicited in immunized animals (cryoEMPEM). Mutational analysis coupled with neutralization assays were used to probe the neutralization potential at each epitope. We demonstrate that cryoEMPEM data can be used for rapid, high-resolution analysis of polyclonal antibody responses without the need for monoclonal antibody isolation. This approach allowed to resolve structurally distinct classes of antibodies that bind overlapping sites. In addition to comprehensive mapping of commonly targeted neutralizing and non-neutralizing epitopes in BG505 SOSIP immunogens, our analysis revealed that epitopes comprising engineered stabilizing mutations and of partially occupied glycosylation sites can be immunogenic. |
DOI | 10.1038/s41467-021-25087-4 |
Alternate Journal | Nat Commun |
PubMed ID | 34376662 |
PubMed Central ID | PMC8355326 |
Grant List | UM1 AI144462 / AI / NIAID NIH HHS / United States UM1 AI100663 / AI / NIAID NIH HHS / United States P51 OD011132 / OD / NIH HHS / United States UL1 TR001442 / TR / NCATS NIH HHS / United States / HHMI / Howard Hughes Medical Institute / United States R01 AI136621 / AI / NIAID NIH HHS / United States F31 AI131873 / AI / NIAID NIH HHS / United States P30 AI036214 / AI / NIAID NIH HHS / United States P01 AI110657 / AI / NIAID NIH HHS / United States U42 OD011023 / OD / NIH HHS / United States |
Submitted by ljc4002 on August 21, 2025 - 3:08pm